ARK News

News
all
press releases
Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.
Stocktwits
Visser said that crypto's real customer hasn't arrived yet, adding that "Crypto is not made for humans," naming AI agents as the real demand.
Stocktwits
The Treasury General Account balance has declined, indicating that the government is bringing capital back into the markets, despite the tiny decline.
Stocktwits

Advertisement|Remove ads.